[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-328273-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-328273-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","surface-bioengineered-extracellular-vesicles-seeking-molecular-biotargets-in-lung-cancer-cells","Surface-Bioengineered Extracellular Vesicles Seeking Molecular Biotargets in Lung Cancer Cells","","Personalized medicine is presented as an approach to modern oncology. The study functionalizes extracellular vesicles (EVs) derived from lung cancer cells by decorating the EV membrane with a targeting heptapeptide ligand. The PTHTRWA heptapeptide is attached via its C- or N-terminal end. Bioconstruct exposure includes model lipid membranes and human A549 and BEAS-2B cells. In vivo, MRI indicates intravenously dosed PTHTRWA-bioengineered EVs accumulate in tumors in NUDE Balb/c mice bearing A549 cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/surface-bioengineered-extracellular-vesicles-seeking-molecular-biotargets-in-lung-cancer-cells/328273/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/surface-bioengineered-extracellular-vesicles-seeking-molecular-biotargets-in-lung-cancer-cells/328273.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were the extracellular vesicles engineered for lung cancer targeting?","Question",{"text":63,"@type":64},"The EV membrane was functionalized with the specific heptapeptide PTHTRWA to enable targeting. The functionalization was performed through either the C- or N-terminal end of the heptapeptide.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which experimental models were used to test the engineered EVs?",{"text":68,"@type":64},"The study used model lipid membranes mimicking normal and cancerous cell membranes, as well as human A549 lung cancer epithelial cells and human BEAS-2B normal bronchial epithelial cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports that the engineered EVs reach tumors in vivo?",{"text":72,"@type":64},"Magnetic resonance imaging (MRI) showed that PTHTRWA-bioengineered EVs loaded with superparamagnetic iron oxide nanoparticle cargos reached growing tumors when administered intravenously to NUDE Balb/c mice bearing A549 cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},328273,1790155134,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","This article is licensed under CC-BY 4.0   \n[www.acsami.org](www.acsami.org)  Research Article   \nSurface-Bioengineered Extracellular Vesicles Seeking Molecular Biotargets in Lung Cancer Cells  \nAgata Kowalczyk, Damian Dziubak, Artur Kasprzak, Kamil Sobczak, Monika Ruzycka-Ayoush, Magdalena Bamburowicz-Klimkowska, Sławomir Sęk, Ivan Rios-Mondragon, Teresa ołek, Elise Runden-Pran, Sergey Shaposhnikov, Mihaela Roxana Cimpan, Maria Dusinska, Ireneusz P. Grudzinski, * and Anna M. Nowicka *  \n Cite This: ACS Appl. Mater. Interfaces 2024, 16, 31997−32016  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Personalized medicine is a new approach to modern oncology. Here, to facilitate the application of extracellular vesicles (EVs) derived from lung cancer cells as potent advanced therapy medicinal products in lung cancer, the EV membrane was functionalized with a specific ligand for targeting purposes. In this role, the most effective heptapeptide in binding to lung cancer cells (PTHTRWA) was used. The functionalization process of EV surface was performed through the C- or N-terminal end of the heptapeptide. To prove the activity of the EVs functionalized with PTHTRWA, both a model of lipid membrane mimicking normal and cancerous cell membranes as well as human adenocarcinomic alveolar basal epithelial cells (A549) and human normal bronchial  \nepithelial cells (BEAS-2B) have been exposed to these bioconstructs. Magnetic resonance imaging (MRI) showed that the asbioengineered PTHTRWA-EVs loaded with superparamagnetic iron oxide nanoparticle (SPIO) cargos reach the growing tumor when dosed intravenously in NUDE Balb/c mice bearing A549 cancer. Molecular dynamics (MD) in silico studies elucidated a high affinity of the synthesized peptide to the α5β1 integrin. Preclinical safety assays did not evidence any cytotoxic or genotoxic effects of the PTHTRWA-bioengineered EVs.  \nKEYWORDS: extracellular vesicle bioengineering, model lipid membrane, lung cancer cells, NUDE mice, preclinical safety  \n1. INTRODUCTION  \nExtracellular vesicles are small membrane-bound vesicles secreted by various cell types, including immune cells, stem cells, and cancer cells. These vesicles range in size from 30 to 150 nm in diameter and are composed of lipids, proteins, and nucleic acids.1 EVs are formed through the inward budding of the endosomal membrane, resulting in the formation of multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs). These MVBs can then fuse with the plasma membrane, releasing the ILVs into the extracellular environment as exosomes.2 Extracellular vesicles play important roles in intracellular communication and are thought to function in a variety of physiological and pathological processes, including immune modulation, tissue regeneration, and cancer progression.3 They also can transfer a variety of molecular cargos, including proteins, lipids, and nucleic acids, between the cells altering the phenotype and behavior of recipient cells.4 The protein content of extracellular vesicles is highly diverse, and it can vary depending on the cell type that secretes them.5−8 Lipids in EVs include phospholipids, cholesterol, and sphingolipids.9 The nucleic acids in EVs are primarily composed of RNA  \nspecies, including mRNA, microRNA, and other small noncoding RNA species.9 Extracellular vesicles are capable of crossing biological barriers such as the blood−brain barrier and can deliver their cargo to specific target cells.4,9, 10 Due to their ability to transfer biologically active molecules, EVs have garnered significant interest in recent years as potential therapeutic agents, targeted transporters, or diagnostic tools, especially based on liquid biopsies. 11, 12 Moreover, extracellular vesicles can be used with other cancer therapies, such as chemotherapy or radiation therapy, so-called combination therapy","cbCaiogiIMOy7bv4","https://ap.wps.com/l/cbCaiogiIMOy7bv4","pdf",3717180,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Extracellular vesicles: origin and roles\n## Therapeutic potential and applications","[{\"question\":\"How were the extracellular vesicles engineered for lung cancer targeting?\",\"answer\":\"The EV membrane was functionalized with the specific heptapeptide PTHTRWA to enable targeting. The functionalization was performed through either the C- or N-terminal end of the heptapeptide.\"},{\"question\":\"Which experimental models were used to test the engineered EVs?\",\"answer\":\"The study used model lipid membranes mimicking normal and cancerous cell membranes, as well as human A549 lung cancer epithelial cells and human BEAS-2B normal bronchial epithelial cells.\"},{\"question\":\"What evidence supports that the engineered EVs reach tumors in vivo?\",\"answer\":\"Magnetic resonance imaging (MRI) showed that PTHTRWA-bioengineered EVs loaded with superparamagnetic iron oxide nanoparticle cargos reached growing tumors when administered intravenously to NUDE Balb/c mice bearing A549 cancer.\"}]","Surface-Bioengineered Extracellular Vesicles Seeking Molecular Biotargets in Lung Cancer Cells | PDF",1789979130]